Covid-19 Convalescent Plasma and Monoclonal Antibodies Treatment of Immunocompromised Patients

Inclusion criteria: * Adult patient * Immunocompromised patient (solid neoplasia, malignant hemopathy, solid organ transplantation, primary immune deficiency, systemic disease, chronic inflammatory disease, etc.) * Hospitalized between 25/02/2020 and 15/01/2023 at HUS, ICANS, CH Colmar and CH Mulhouse * Having received curative monoclonal antibody treatment or convalescent plasma treatment for SARS-Cov2 infection * Patient who has not expressed, after being informed, his opposition to the reuse of his data for scientific research purposes. Exclusion criteria: * Subject who expressed their opposition to participating in the study * Subject under guardianship, curatorship or safeguard of justice